World Journal of Urology

, Volume 37, Issue 4, pp 709–718 | Cite as

Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia

  • Pil Moon Kang
  • Young Jin Kim
  • Won Tae Seo
  • Su Hwan Kang
  • Taek Sang Kim
  • Bong Kwon Chun
  • Won Ik Seo
  • Jee-Yeong JeongEmail author
  • Jae Il ChungEmail author
Original Article



The enzyme 5-α reductase type 2 (5-AR 2) plays a key role in the development and maintenance of the prostate gland. We evaluated the level 5-AR 2 protein expression and the relationship between methylation of the 5-AR 2 gene-promoter and 5-AR 2 protein expression of benign prostatic hyperplasia (BPH).

Materials and methods

A total of 37 prostate samples were evaluated. These included 22 samples from men undergoing transurethral prostate resections and 15 non-cancerous transition-zone human prostate tissue samples taken following radical prostatectomy. We quantified 5-AR 2 protein expression and gene-promoter methylation status using common assay procedures. Clinical variables included age, body mass index (BMI), prostate-specific antigen (PSA) levels, lipid profiles, and prostate volumes. Univariate and multivariate statistical analyses were performed followed by stepwise logistic regression modeling.


We were able to extract DNA from 36 of the 37 tissue samples and 10 of these (28%) did not express the 5-AR 2 protein. In total, 26 patients (72%) had methylated 5-AR 2 promoter-regions. There was a strong correlation between methylation of the 5-AR 2 promoter-regions and low-absent 5-AR 2 protein expression (p = 0.0003). Increasing age significantly predicted methylation status and protein expression level (p = 0.013).


The level of 5-AR 2 protein expression varies among prostate tissue samples. Methylation of the 5-AR 2 gene-promoter may account for low or absent expression of 5-AR 2 in adult human prostate tissues. Increased age correlates with increased 5-AR 2 gene-promoter methylation and decreased protein expression in men with BPH.


5-α Reductase DNA Hyperplasia Methylation Prostate 



This study was supported in part by a grant from Kosin University College of Medicine (2016) (to P.M.K), and also by Korea National Research Foundation (KNRF) grants 2015M3A9B6073646, 2015R1D1A1A01058387 and 2017M3A9G7072564 (to J.Y.J).

Author contributions

PMK: first author, conception and design, drafting the manuscript, statistical analysis, YJK: co-first author (PMK and YJK contributed equally to the work) performed the experiments (Tissue processing, DNA extraction and methylation analysis), WTS: protocol/project development, data analysis, SHK: critical revision of the manuscript for scientific and factual content, TSK: critical revision of the manuscript for scientific and factual content, BKC: pathological examination, immunohistochemistry analysis, WIS: critical revision of the manuscript for scientific and factual content, JYJ: co-corresponding author (JYJ and JIC contributed equally to the work) contributed reagents/materials/analysis tools, JIC: conception and design, Supervision.

Compliance with ethical standards

Conflict of interest

The author(s) declare that they have no competing interests.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Roehrborn CG (2008) Pathology of benign prostatic hyperplasia. Int J Impot Res 20(Suppl 3):S8–S11Google Scholar
  2. 2.
    Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132(3):474–479CrossRefGoogle Scholar
  3. 3.
    Shapiro E, Becich MJ, Hartanto V, Lepor H (1992) The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147(5):1293–1297CrossRefGoogle Scholar
  4. 4.
    Marcelli M, Cunningham GR (1999) Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 84(10):3463–3468Google Scholar
  5. 5.
    Langlois VS, Zhang D, Cooke GM, Trudeau VL (2010) Evolution of steroid 5-alpha reductases and comparison of their function with 5-beta reductase. Gen Comp Endocrinol 166(3):489–497CrossRefGoogle Scholar
  6. 6.
    Azzouni F, Godoy A, Li Y, Mohler J (2012) The 5-alpha reductase isozyme family: a review of the basic biology and their role in human diseases. Adv Urol 2012:530121CrossRefGoogle Scholar
  7. 7.
    Russell DW, Wilson JD (1994) Steroid 5-alpha reductase: two genes/two enzymes. Ann Rev Biochem 63:25–61CrossRefGoogle Scholar
  8. 8.
    Carson C, Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61(4 Suppl. 1):2–7CrossRefGoogle Scholar
  9. 9.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT (2006) Pharmacologic basis for the enhanced efficacy of dutasteride against prostate cancers. Clin Cancer Res 12(13):4072–4079CrossRefGoogle Scholar
  10. 10.
    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338:557–563CrossRefGoogle Scholar
  11. 11.
    Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N (2005) Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5-alpha reductase inhibitor dutasteride: results of 4-year studies. BJU Int 96(4):572–577CrossRefGoogle Scholar
  12. 12.
    Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED (1998) Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 52(2):195–202CrossRefGoogle Scholar
  13. 13.
    Hong SJ, Ko WJ, Kim SI, Chung BH (2003) Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol 44(1):94–99CrossRefGoogle Scholar
  14. 14.
    Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 11(10):726–734CrossRefGoogle Scholar
  15. 15.
    Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683–692CrossRefGoogle Scholar
  16. 16.
    Bechis SK, Otsetov AG, Ge R, Olumi AF (2014) Personalized medicine for management of benign prostatic hyperplasia. J Urol 192(1):16–23CrossRefGoogle Scholar
  17. 17.
    Steers WD (2001) 5-alpha reductase activity in the prostate. Urology 58(6 Suppl 1):17–24CrossRefGoogle Scholar
  18. 18.
    Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD (1974) Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291(18):944–949CrossRefGoogle Scholar
  19. 19.
    Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974) Steroid 5-alpha reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186(4170):1213–1215CrossRefGoogle Scholar
  20. 20.
    Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL et al (2011) Reduced levels of 5-a reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate 71(12):1317–1324Google Scholar
  21. 21.
    Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL et al (2015) Age and obesity promote methylation and suppression of 5-α reductase 2: implications for personalized therapy of benign prostatic hyperplasia. J Urol 194(4):1031–1037CrossRefGoogle Scholar
  22. 22.
    Dobosy JR, Roberts JL, Fu VX, Jarrard DF (2007) The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177(3):822–831CrossRefGoogle Scholar
  23. 23.
    Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Müller SC et al (2005) Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 11(11):4097–4106CrossRefGoogle Scholar
  24. 24.
    Calvanese V, Lara E, Kahn A, Fraga MF (2009) The role of epigenetics in aging and age-related diseases. Ageing Res Rev 8(4):268–276CrossRefGoogle Scholar
  25. 25.
    Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148–1159CrossRefGoogle Scholar
  26. 26.
    Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD (1974) Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291(18):944–949CrossRefGoogle Scholar
  27. 27.
    Frazier-Wood AC, Aslibekyan S, Absher DM, Hopkins PN, Sha J, Tsai MY et al (2014) Methylation at CPT1A locus is associated with lipoprotein subfraction profiles. J Lipid Res 55(7):1324–1330CrossRefGoogle Scholar
  28. 28.
    Gagnon F, Aissi D, Carrie A, Morange PE, Tregouet DA (2014) Robust validation of methylation levels association at CPT1A locus with lipid plasma levels. J Lipid Res 55(7):89–91CrossRefGoogle Scholar
  29. 29.
    Pfeiffer L, Wahl S, Pilling LC, Reischl E, Sandling JK, Kunze S et al (2015) DNA methylation of lipid related genes affects blood lipid levels. Circ Cardiovasc Genet 8(2):334–342CrossRefGoogle Scholar
  30. 30.
    Lamon-Fava S, Wilson PW, Schaefer EJ (1996) Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Biol 16(12):1509–1515CrossRefGoogle Scholar
  31. 31.
    Brown C, Higgins M, Donato K, Rohde F, Garrison R, Obarzanek E et al (2000) Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 8(9):605–619CrossRefGoogle Scholar
  32. 32.
    Alexander J (2001) Obesity and coronary heart disease. Am J Med Sci 321(4):215–224CrossRefGoogle Scholar
  33. 33.
    Gostynski M, Gutzwiller F, Kuulasmaa K, Döring A, Ferrario M, Grafnetter D et al (2004) Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project. Int J Obes 28(8):1082–1090CrossRefGoogle Scholar
  34. 34.
    Benton MC, Johnstone A, Eccles D, Harmon B, Hayes MT, Lea RA et al (2015) An analysis of DNA methylation in human adipose tissue reveals differential modification of obesity genes before and after gastric bypass and weight loss. Genome Biol 22(16):8CrossRefGoogle Scholar
  35. 35.
    Dick KJ, Nelson CP, Tsaprouni L, Sandling JK, Aissi D, Wahl S et al (2014) DNA methylation and body-mass index: a genomewide analysis. Lancet 383(9933):1990–1998CrossRefGoogle Scholar
  36. 36.
    Barres R, Kirchner H, Rasmussen M, Yan J, Kantor FR, Krook A et al (2013) Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep 3(4):1020–1207CrossRefGoogle Scholar
  37. 37.
    Issa JP (2014) Aging and epigenetic drift: a vicious cycle. J Clin Invest 124(1):24–29CrossRefGoogle Scholar
  38. 38.
    Niwa T, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T et al (2010) Inflammatory processes triggered by helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 70(4):1430–1440CrossRefGoogle Scholar
  39. 39.
    Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD et al (2008) Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 68(24):10280–10289CrossRefGoogle Scholar
  40. 40.
    Kim J, Kim JY, Song KS, Lee YH, Seo JS, Jelinek J et al (2007) Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in vitro vascular senescence. Biochim Biophys Acta 1772(1):72–80CrossRefGoogle Scholar
  41. 41.
    Teitell M, Richardson B (2003) DNA methylation in the immune system. Clin Immunol 109(1):2–5CrossRefGoogle Scholar
  42. 42.
    Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O’Brien SP et al (2005) Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63(3):231–239CrossRefGoogle Scholar
  43. 43.
    Titus MA, Gregory CW, Ford OH 3rd, Schell MJ, Maygarden SJ, Mohler JL (2005) Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11(12):4365–4371CrossRefGoogle Scholar
  44. 44.
    Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ (2008) Type 1 and type 2 5 alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 53(2):244–252CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Pil Moon Kang
    • 1
  • Young Jin Kim
    • 2
    • 3
  • Won Tae Seo
    • 1
  • Su Hwan Kang
    • 1
  • Taek Sang Kim
    • 1
  • Bong Kwon Chun
    • 4
  • Won Ik Seo
    • 5
  • Jee-Yeong Jeong
    • 2
    • 3
    Email author
  • Jae Il Chung
    • 5
    Email author
  1. 1.Department of Urology, Kosin Gospel HospitalKosin University College of MedicineBusanKorea
  2. 2.Department of BiochemistryKosin University College of MedicineBusanKorea
  3. 3.Cancer Research InstituteKosin University College of MedicineBusanKorea
  4. 4.Department of PathologyKosin University College of MedicineBusanKorea
  5. 5.Department of Urology, Busan Paik HospitalInje University College of MedicineBusanKorea

Personalised recommendations